

Pharmacy & Therapeutics Committee

Meeting Minutes

Thursday, September 19th, 2024

7:00 a.m. to 8:45 a.m.

Video Call: meet.google.com/tni-wias-qke

Committee Members Present:

Cole Sloan, PharmD, BCPS, BCGP, Committee Chair

Bryan Larson, PharmD, P&T Manager

Rocky Parker, PharmD, MBA

Susan Siegfroid, MD

Clayton Grace, RPh

Committee Members Excused: None

Dept. of Health/Div. of Health Care Financing Staff Present:

Yoon Kim-Butterfield, MD

Sepideh Daery, PharmD

Ngan Huynh, PharmD

Stephanie Byrne, PharmD

Luis Moreno, PharmD, CDCES

Trevor Smith, BS, CPHT

Accountable Care Organization (ACO) Staff Presenters:

San Tran, PharmD, HealthChoice

Heidi Goodrich, Molina

Laura Britton, PharmD, HealthyU

Samantha Eshelman, PharmD, Select Health

University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzales, PharmD

Other Individuals Present:

Amy Hale, Johnson and Johnson

Lauren Heath, PharmD, DRRC

Artia Solutions

Jason Smith

Jessi Bennett, BioCryst

Kelly Sullivan

Leslie Costalin, Otsuka

Lisa Pulver, Johnson & Johnson

Monet Luloh, PharmD, DRRC

Natalie Rose, Gilead

Giuseppe Miranda, PhD, BioCryst

Stephen

Pharmacy & Therapeutics Committee

Meeting Minutes

Meeting conducted by: Committee Chair

1. **Opening & Welcome:** Committee Chair opened the meeting and announced quorum.
2. **Housekeeping:** Cole Sloan thanked Dr. Michelle Hofman for her services on the P&T Committee.
3. **Review and Approval of May P&T Minutes:** Rocky Parker made a motion to approve the minutes. Bryan Larson seconded the motion. Clayton Grace abstained from the motion. The rest in favor, motion passed.
4. **Drug Utilization Review (DUR) Board update:**
 - a. The DUR board met in June to discuss concurrent use of muscle relaxants and/or sedative-hypnotics with opioids
 - b. The DUR board met in July to discuss concomitant use of stimulants for ADHD and Sedative-Hypnotics.
 - c. The DUR board met last week in September to discuss antipsychotics used in adults.
5. **Topic: Accountable Care Organization (ACO) Update: Report on Methodologies for Preferred Drug List Development**
 - a. San Tran presented HealthChoice's methodology
 - b. Laura Britton presented HealthyU's methodology
 - c. Heidi Goodrich presented Molina's methodology
 - d. Samantha Eshelman presented Select Health's methodology
6. **Topic: Hereditary Angioedema (HAE)**
 - a. Presented by Valerie Gonzales
7. **Public Comment:**
 - a. Giuseppe Miranda, PhD from BioCryst manufacture for Orladeyo (berotralstat)
8. **Committee Discussion:**
 - a. Bryan Larson suggested having at least one self-administered agent as

Pharmacy & Therapeutics Committee

Meeting Minutes

a preferred product on the PDL and if the committee should consider having a separate short-term prophylaxis class or just simply prophylaxis treatments.

- b. Susan Siegfroid recommended Danazol as a non-preferred product considering the risks outweigh the benefits. She mentioned that for the HAE Prior Authorization that was brought up in the DUR last week, the DUR Board recommended having at least two doses available for any of the on-demand treatments.
- c. Susan Siegfroid motioned to have Danazol as a non-preferred product, and at least two doses of any on-demand treatments be available when applicable. She motioned to add grandfathering clauses for patients who are already stable on prophylaxis and on-demand treatments. Clayton Grace seconded. All in motion. Motion passed. Cole Sloan was not present for this motion.
- d. Bryan Larson motioned to have at least one preferred acute treatment and one preferred prophylaxis treatment that are self-administered. Rocky Parker seconded. All in favor. Motion passed. Cole Sloan was not present for this motion.

9. **Public Meeting Adjourned:** Susan Siegfroid motioned to adjourn the meeting. Bryan Larson seconded the motion. Unanimous Approval.

10. **Next meeting: Nov 21th, 2024.**

- a. Topic: Duchenne Muscular Dystrophy (DMD).

Audio recording of all P&T meetings are available online at:
https://www.youtube.com/@dmhf_webdohdhhs2